The life sciences industry in Indiana employs 55,500 workers paying average wages of more than $88,500 per year, according to new figures released Tuesday by Indianapolis-based life sciences development group BioCrossroads.
The Indiana Applied Research Enterprise already has received support from John Lechleiter, CEO of Indianapolis-based Eli Lilly and Co., as a place for collaboration between academic and industrial scientists.
Joseph Kelsay, who had served as director of Indiana’s Department of Agriculture since 2009, is joining Dow AgroSciences’ government affairs team as senior manager of biotechnology affairs.
Local startups Esanex Inc. and Algaeon Inc. have received $500,000 and $250,000, respectively, from Indiana Seed Fund II, BioCrossroads’ second fund to help fledgling life sciences companies.
The Indiana Economic Development Corp. is looking to renew its commitment to life sciences by creating a $30 million venture fund. The amount dedicated to one sector would be equal to the state’s allocation for all high-tech startups over the past two years.
The money is the state's share of a $42.9 million deal the drugmaker struck to resolve allegations it deceptively marketed an antibacterial agent and promoted a fibromyalgia treatment for off-label uses.
Eli Lilly will launch another study of its possible Alzheimer's treatment solanezumab, a move that delays a regulatory decision on a drug that flashed potential to help patients with mild cases of the fatal disease.
Richard DiMarchi helped develop the sepsis-treating drug Xigris for Eli Lilly and Co. He also co-founded Marcadia Biotech, which Roche acquired in 2010 for an initial upfront payment of $287 million.
Indianapolis-based Nico Corp. wants to use its new round of capital to develop brain surgery products to address diseases that were often considered inoperable, such as metastatic brain cancer and intracerebral hemorrhages.
A North Carolina-based maker of cancer-fighting ultrasound machines plans to create 27 jobs paying an average of $36 an hour at its Indianapolis facility over the next three years.
Early-stage venture capital has been harder and harder to come by for life sciences companies in recent years, but two Indianapolis investors are working to raise sizable funds to help fill the gap.
Bloomington-based Cook Medical won approval for the first drug-coated stent for clogged leg arteries in the United States, which accounts for 40 percent of the soon-to-be $3 billion market.
LabDoor, which soon will launch an iPhone app that assigns A-F grades to over-the-counter vitamins and medicines, moved last month from Indianapolis to San Francisco, where it received $100,000 in startup financing.
Indianapolis-based Indigo Biosystems Inc., a scientific software provider, announced Monday morning that it plans to add 63 jobs by 2015 as part of a $1.4 million expansion.
If a biotech startup were akin to a rock band, Kristin Sherman might be the keyboardist. She’s not front-and-center on the stage, but the ballad wouldn’t be as dynamic without her pounding the chords.
Community Health Network thinks it can help patients, engage doctors and maybe even make some money by trying to turn ideas within its organization into commercial products, service and companies.
Indianapolis-based BioStorage Technologies Inc. is planning to add 108 jobs in the next five years as part of a $7 million expansion and is seeking financial incentives from the city for the second time in three years.
About 100 workers will staff the new plant, which will be constructed by spring 2014 and ready for operations in 2015. But only “some” of that number will be new hires.
Pete Kissinger hopes Phlebotics will follow in the footsteps of another of his creations, Bioanalytical Systems Inc.
BioCrossroads CEO David Johnson sees little conflict as he balances all three in promoting and investing in Indiana life sciences firms
